Role of the human high-affinity copper transporter in copper homeostasis regulation and cisplatin sensitivity in cancer chemotherapy

Cancer Research

Volumn 72, Issue 18, 2012, Pages 4616-4621

  Kuo, Macus Tien ^a   Fu, Siqing ^b   Savaraj, Niramol ^c   Chen, Helen H W ^d,e  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d Medical College and Hospital   (Taiwan)

^e NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CARRIER PROTEIN; CISPLATIN; COPPER; COPPER TRANSPORTER 1; GLUTAMATE CYSTEINE LIGASE; GLUTATHIONE; PLATINUM COMPLEX; PREGNANCY SPECIFIC BETA1 GLYCOPROTEIN; THIOMOLYBDIC ACID; TRIENTINE; UNCLASSIFIED DRUG; ZINC FINGER PROTEIN;

ANEMIA; APOPTOSIS; BINDING AFFINITY; BONE MARROW SUPPRESSION; CHELATION THERAPY; CHEMOSENSITIZATION; DRUG EFFICACY; DRUG SAFETY; DRUG SENSITIVITY; DRUG UPTAKE; HOMEOSTASIS; HUMAN; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN CROSS LINKING; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN SYNTHESIS; REVIEW; TRANSCRIPTION REGULATION; UPREGULATION; WILSON DISEASE;

ANTINEOPLASTIC AGENTS; CATION TRANSPORT PROTEINS; CISPLATIN; COPPER; DRUG RESISTANCE, NEOPLASM; HOMEOSTASIS; HUMANS; NEOPLASMS;

EID: 84866426370     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-0888     Document Type: Review

References (31)

1. Ishida S, Lee J, Thiele DJ, Herskowitz I. Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. Proc Natl Acad Sci U S A 2002;99:14298-302.
2. HallMD, OkabeM, Shen DW, Liang XJ, GottesmanMM. The role of cellular accumulation in determining sensitivity to platinumbased chemotherapy. Annu Rev Pharmacol Toxicol 2008;48:495-535.
3. Wang D, Lippard SJ. Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 2005;4:307-20.
4. Liang ZD, Stockton D, Savaraj N, Tien Kuo M. Mechanistic comparison of human high-affinity copper transporter 1-mediated transport between copper ion and cisplatin. Mol Pharmacol 2009;76:843-53.
5. Gatti L, Chen D, Beretta GL, Rustici G, Carenini N,Corna E, et al. Global gene expression of fission yeast in response to cisplatin. Cell Mol Life Sci 2004;61:2253-63.
6. Beretta GL, Gatti L, Tinelli S, Corna E, Colangelo D, Zunino F, et al. Cellular pharmacology of cisplatin in relation to the expression of human copper transporter CTR1 in different pairs of cisplatin-sensitive and -resistant cells. Biochem Pharmacol 2004;68:283-91.
7. Howell SB, Safaei R, Larson CA, Sailor MJ. Copper transporters and the cellular pharmacology of the platinum-containing cancer drugs. Mol Pharmacol 2010;77:887-94.
8. Kuo MT, Chen HH, Song IS, Savaraj N, Ishikawa T. The roles of copper transporters in cisplatin resistance. Cancer Metastasis Rev 2007;26:71-83.
9. Holzer AK, Manorek GH, Howell SB. Contribution of the major copper influx transporter CTR1 to the cellular accumulation of cisplatin, carboplatin, and oxaliplatin. Mol Pharmacol 2006;70:1390-4.
10. Ishida S, McCormick F, Smith-McCune K, Hanahan D. Enhancing tumor-specific uptake of the anticancer drug cisplatin with a copper chelator. Cancer Cell 2010;17:574-83.
11. Tothill RW, Tinker AV, George J, Brown R, Fox SB, Lade S, et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res 2008;14:5198-208.
12. Liang ZD, Long Y, Tsai WB, Fu S, Kurzrock R, Gagea-Iurascu M, et al. Mechanistic basis for overcoming platinum resistance using copper chelating agents. Mol Cancer Ther 2012 Aug 21 [Epub ahead of print].
13. Chen HH, Yan JJ, Chen WC, Kuo MT, Lai YH, Lai WW, et al. Predictive and prognostic value of human copper transporter 1 (hCtr1) in patients with stage III non-small-cell lung cancer receiving first-line platinum-based doublet chemotherapy. Lung Cancer 2012;75:228-34.
14. Chen HH, Song IS, Hossain A, Choi M-K, Yamane Y, Liang ZD, et al. Elevated glutathione levels confer cellular sensitization to cisplatin toxicity by up-regulation of copper transporter hCtr1. Mol Pharmacol 2008;74:697-704.
15. Liang ZD, Tsai WB, Lee MY, Savaraj N, Kuo MT. Specifi city protein 1 (sp1) oscillation is involved in copper homeostasis maintenance by regulating human high-affinity copper transporter 1 expression. Mol Pharmacol 2012;81:455-64.
16. Song IS, Chen HH, Aiba I, Hossain A, Liang ZD, Klomp LW, et al. Transcription factor Sp1 plays an important role in the regulation of copper homeostasis in mammalian cells. Mol Pharmacol 2008;74:705-13.
17. Fu S, Naing A, Fu C, Kuo MT, Kurzrock R. Overcoming platinum resistance through the use of a copper-lowering agent. Mol Cancer Ther 2012;11:1221-5.
18. Chen HH, Kuo MT. Role of glutathione in the regulation of Cisplatin resistance in cancer chemotherapy. Met Based Drugs 2010;2010:1-7.
19. Festa RA, Thiele DJ. Copper: an essential metal in biology. Curr Biol 2011;21:R877-83.
20. Guo Y, Smith K, Lee J, Thiele DJ, Petris MJ. Identification of methionine-rich clusters that regulate copper-stimulated endocytosis of the human Ctr1 copper transporter. J Biol Chem 2004;279:17428-33.
21. Molloy SA, Kaplan JH. Copper-dependent recycling of hCTR1, the human high affinity copper transporter. J Biol Chem 2009;284:29704-13.
22. Holzer AK, Howell SB. The internalization and degradation of human copper transporter 1 following cisplatin exposure. Cancer Res 2006;66:10944-52.
23. Guo Y, Smith K, Petris MJ. Cisplatin stabilizes a multimeric complex of the human Ctr1 copper transporter: requirement for the extracellular methionine-rich clusters. J Biol Chem 2004;279:46393-9.
24. Nose Y, Wood LK, KimBE, Prohaska JR, Fry RS, Spears JW, et al. Ctr1 is an apical copper transporter in mammalian intestinal epithelial cells in vivo that is controlled at the level of protein stability. J Biol Chem 2010;285:32385-92.
25. Gupte A, Mumper RJ. Elevated copper and oxidative stress in cancer cells as a target for cancer treatment. Cancer Treat Rev 2009;35:32-46.
26. Brewer GJ. The use of copper-lowering therapy with tetrathiomolybdate in medicine. Expert Opin Investig Drugs 2009;18:89-97.
27. Dmitriev OY. Mechanism of tumor resistance to cisplatin mediated by the copper transporter ATP7B. Biochem Cell Biol 2011;89:138-47.
28. Blair BG, Larson CA, Adams PL, Abada PB, Pesce CE, Safaei R, et al. Copper transporter 2 regulates endocytosis and controls tumor growth and sensitivity to cisplatin in vivo. Mol Pharmacol 2011;79:157-66.
29. Lee J, Prohaska JR, Dagenais SL, Glover TW, Thiele DJ. Isolation of a murine copper transporter gene, tissue specific expression and functional complementation of a yeast copper transport mutant. Gene 2000;254:87-96.
30. Kuo YM, Gybina AA, Pyatskowit JW, Gitschier J, Prohaska JR. Copper transport protein (Ctr1) levels in mice are tissue specific and dependent on copper status. J Nutr 2006;136:21-6.
31. Bertolini G, Roz L, Perego P, Tortoreto M, Fontanella E, Gatti L, et al. Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment. Proc Natl Acad Sci U S A 2009;106:16281-6.